Sentinel Oncology Ltd Sign Exclusive Worldwide License Agreement with PharmaEngine, Inc for the Rights to Develop and Commercialise SOL578, a Small Molecule Chk1 Inhibitor
Cambridge, UK, September 26, 2022 – Sentinel Oncology Limited today announced that it has entered into an exclusive license agreement with Taiwan based pharmaceutical company PharmaEngine, Inc. (TWO: 4162) to advance the development of SOL578, their checkpoint kinase 1 (Chk1) inhibitor.
Under the terms of the agreement, Sentinel is eligible to receive $140.5 million from development, regulatory and sales milestones in addition to royalties from net product sales of SOL578.
Robert Boyle, CEO of Sentinel Oncology commented: “We are delighted to have reached this significant milestone in our collaboration with PharmaEngine – this licence agreement provides important validation of the internal discovery capabilities at Sentinel Oncology and our efforts to develop best in class treatments for cancer. We look forward to the next exciting phase of development for SOL578 as it progresses into the clinic.“
About Sentinel Oncology Limited
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a fully integrated drug discovery company developing and commercializing high quality drug candidates for cancer and other diseases where there is currently an unmet medical need. Our pipeline is focused on the design and optimisation of new drugs which can be used to treat primary brain tumors or systemic tumors which frequently metastasise to the brain. Find out more by visiting Sentinel Oncology’s website at https://www.sentineloncology.com.
About PharmaEngine (TWO: 4162)
PharmaEngine, Inc. is a commercial stage oncology company headquartered in Taipei, focusing on the development of new medications for the treatment of cancer. PharmaEngine, Inc. has projects ongoing: ONIVYDE® (Irinotecan Liposome Injection), a commercial drug product which receives marketing authorizations more than 40 countries worldwide, including Taiwan, US, EU, Australia, Canada, Japan, South Korea, Singapore, and China, for the treatment of metastatic pancreatic cancer patients who have progressed on gemcitabine; PEP07, a CHK1 inhibitor which is under development at pre-clinical stage. For further information, please visit PharmaEngine’s website at https://www.pharmaengine.com.